Market Access News
pan-Canadian Pharmaceutical Alliance (pCPA): July 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of July 31, 2019. Highlights since the last update include: 5 products completed CADTH review, for a total of 12 files under consideration; 7 products initiated pCPA negotiations, for a total of 47 active negotiations; 6 negotiations completed for a total of 263 completed negotiations; 3 negotiations…
pan-Canadian Pharmaceutical Alliance (pCPA): June 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of June 30, 2019. Highlights since the last update include: 6 products completed CADTH review, for a total of 15 files under consideration; 9 products initiated pCPA negotiations, for a total of 49 active negotiations; 4 negotiations completed for a total of 257 completed negotiations; 3 negotiations…
pan-Canadian Pharmaceutical Alliance (pCPA): May 2019 Trends and Insights The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of May 31, 2019. Highlights since the last update include: 2 negotiations completed for a total of 253 completed negotiations; 2 negotiations closed, for a total of 37 closed negotiations; 1 file closed without negotiations, for a total of 65 declined negotiations; 10 products completed CADTH review,…
pan-Canadian Pharmaceutical Alliance (pCPA): April 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of April 30, 2019. Highlights since the last update include: 4 negotiations completed for a total of 251 completed negotiations No negotiations closed, for a total of 35 closed negotiations 1 file closed without negotiations, for a total of 64 declined negotiations 4 products completed CADTH review,…
pan-Canadian Pharmaceutical Alliance (pCPA): March 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the status of brand negotiations as of March 31, 2019. Highlights since the last update include: 5 negotiations completed for a total of 247 completed negotiations 2 negotiations closed, for a total of 35 closed negotiations No new files closed without negotiations, for a total of 63 declined negotiations 8 products completed CADTH…
pan-Canadian Pharmaceutical Alliance (pCPA): February 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of February 28, 2019. The key highlights since the last update are: 8 negotiations were completed for a total of 242 completed negotiations No negotiations were closed, for a total of 33 closed negotiations The pCPA decided to decline negotiations on 1 file, for a total…
MORSE Consulting is pleased to release its 2018 pCPA Year in Review infographic. The purpose of this resource is to help market access professionals provide a top-line pCPA performance summary to both internal and external stakeholders. This infographic compares the negotiation activities of the pCPA in 2018 to 2017 as it relates to: completed negotiations by source (CDR, pCODR, pCPA initiated); a breakdown of pCPA initiated files; and completed negotiation…
MORSE Consulting has prepared a summary of the key highlights from the Patented Medicines Prices Review Board’s (PMPRB) recent webinar on the release of their Meds Entry Watch 2017 report (third edition). Date: February 20th 2019 Time: 1pm-2pm Presented by: Elena Lungu (Manager NPDUIS, PMPRB), Jared Berger (Policy Analyst, Policy and Economic Analysis Branch, PMPRB) Objective: To present the Meds Entry Watch, 2017 report to interested stakeholders and allow an…
MORSE Consulting is pleased to release a new report by Stephen Filbey of WestPAR Consulting, one of its strategic partners, entitled A Pharma industry Perspective/Opinion on British Columbia’s 2019 Budget. The NDP Government of BC, under the first non-majority legislature since 1952, has just released its second budget. With a strong economy, balanced operating budget, and an estimated $340 million in surplus over the next year, the NDP under the…
pan-Canadian Pharmaceutical Alliance (pCPA): January 2019 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of January 31, 2019. The key highlights since the last update are: 3 negotiations were completed for a total of 234 completed negotiations 3 negotiations were closed, for a total of 33 closed negotiations The pCPA decided to decline negotiations on 2 files, for a total…
MORSE Consulting is pleased to release a new report entitled Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis. While the majority of Canadians have some form of prescription medication coverage, the speed and extent to which individual patients gain access to new therapies, can vary significantly. As new drugs (and expanded indications for existing drugs) are approved by Health Canada and become available for use…
pan-Canadian Pharmaceutical Alliance (pCPA): December 2018 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) issued the status of brand negotiations as of December 31, 2018. The key highlights since the November update are: 5 products received a final HTA recommendation, for a total of 13 files under consideration 2 products initiated pCPA negotiations, for a total of 46 active negotiations 7 negotiations were completed for a total of…
pan-Canadian Pharmaceutical Alliance (pCPA): November 2018 Negotiation Status Update The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of November 30, 2018. The key highlights since the October update are: 7 new drug products have initiated pCPA negotiations, for a total of 51 active negotiations; 9 negotiations were completed for a total of 225 completed negotiations; and 2 negotiations were closed since the last…
Toronto, December 13, 2018 – Neil Grubert and MORSE Consulting are pleased to announce the release of a new report entitled Pharmaceutical Managed Entry Agreements – Lessons Learned from Europe, the United States, Canada, and Australia. A performance or outcomes-based agreement (OBA) tracks the effectiveness of a drug in a defined patient population over a specified period of time and directly links the price or reimbursement of the product to…
On November 27, 2018 the BC Ministry of Health changed coverage of glatiramer products, GLATECT™ and COPAXONE®, which demonstrates a shift from previous public drug plan approaches for funding of subsequent entry products (biosimilars) for chronic diseases. Background GLATECT™ is the first subsequent entry glatiramer-based treatment available for reimbursement for RRMS in Canada – i.e. a follow on product to Copaxone®. It is classifed as a non-biological complex…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
Browse our Market Access News section - Page 6 of 11 - MORSE Consulting Inc.
